Amplification of BCL2, MCL1, and BCL-XL in CLL when venetoclax therapy failed, and the overexpression of these genes in CLL cell line increased the IC50 of venetoclax [39]. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.